Hemispherx Biopharma (HEB) Highlights New Data Showing Ampligen’s Positive Role in Reprograming Tumor Microenvironment
Tweet Send to a Friend
Hemispherx Biopharma, Inc. (NYSE: HEB) announced today that its TLR3 agonist Ampligen outperformed two other TLR3 agonists, poly IC and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
